Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Conditions:   CD30-Positive Neoplastic Cells Present;   Folliculotropic Mycosis Fungoides;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome Interventions:   Drug: Brentuximab Vedotin;   Drug: Lenalidomide;   Other: Laboratory Biomarker Analysis Sponsor:   City of Hope Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials